Passage Bio, Inc. reported its financial results for the third quarter ended September 30, 2024, and provided updates on its business operations.
The company announced the enrollment of four patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing progressing as planned. Updated interim data from Cohort 1 FTD-GRN showed that PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment.
Passage Bio also highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy, which was presented in an oral presentation at ESGCT. The company expects to report 12-month Cohort 1 and interim Cohort 2 data in the first half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.